Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice

Abstract

Advanced pancreatic ductal adenocarcinoma (PDAC) has typically been resistant to chemotherapy and immunotherapy; therefore, novel strategies are needed to enhance therapeutic response. Cholecystokinin (CCK) has been shown to stimulate growth of pancreatic cancer. CCK receptors (CCKRs) are present on pancreatic cancer cells, fibroblasts, and lymphocytes. We… (More)
DOI: 10.1007/s00262-017-2077-9

Topics

3 Figures and Tables

Cite this paper

@article{Smith2017CholecystokininRA, title={Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice}, author={Jill Palmer Smith and Shangzi Wang and Sandeep Nadella and Sandra A. Jablonski and Louis M. Weiner}, journal={Cancer Immunology, Immunotherapy}, year={2017}, pages={1-13} }